BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Povetacicept readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Povetacicept\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07890909-10841@assetmemo.bio
DTSTAMP:20261121T004948Z
DTSTART;VALUE=DATE:20271212
DTEND;VALUE=DATE:20271213
SUMMARY:Povetacicept: Phase 3 readout est. (NCT07890909)
DESCRIPTION:Povetacicept\, phase 3\, IgA Nephropathy.\nStudy: A Phase 3b St
 udy of Participant Experience on Povetacicept Administered Via Autoinjecto
 r as Compared to Sibeprenlimab Administered Via Prefilled Syringe\nEstimat
 ed primary completion: 12 December 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/povetacicept#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07890909
URL:https://assetmemo.bio/drug/povetacicept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06564142-10841@assetmemo.bio
DTSTAMP:20261121T004948Z
DTSTART;VALUE=DATE:20280130
DTEND;VALUE=DATE:20280131
SUMMARY:Povetacicept: Phase 3 readout est. (NCT06564142)
DESCRIPTION:Povetacicept\, phase 3\, IgA Nephropathy.\nStudy: Evaluation of
  Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgA
 N)\nEstimated primary completion: 30 January 2028. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/povetacicept#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06564142
URL:https://assetmemo.bio/drug/povetacicept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05732402-10841@assetmemo.bio
DTSTAMP:20261121T004948Z
DTSTART;VALUE=DATE:20280302
DTEND;VALUE=DATE:20280303
SUMMARY:Povetacicept: Phase 1/2 readout est. (NCT05732402)
DESCRIPTION:Povetacicept\, phase 1/2\, IgA Nephropathy.\nStudy: An Open-lab
 el Study of Povetacicept in Autoantibody-Associated Glomerular Diseases\nE
 stimated primary completion: 2 March 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/povetacicept#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT05732402
URL:https://assetmemo.bio/drug/povetacicept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07501702-10841@assetmemo.bio
DTSTAMP:20261121T004948Z
DTSTART;VALUE=DATE:20290302
DTEND;VALUE=DATE:20290303
SUMMARY:Povetacicept: Phase 2 readout est. (NCT07501702)
DESCRIPTION:Povetacicept\, phase 2\, Myasthenia Gravis.\nStudy: A Phase 2 S
 tudy to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis
 \nEstimated primary completion: 2 March 2029. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/povetacicept#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07501702
URL:https://assetmemo.bio/drug/povetacicept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07204275-10841@assetmemo.bio
DTSTAMP:20261121T004948Z
DTSTART;VALUE=DATE:20290627
DTEND;VALUE=DATE:20290628
SUMMARY:Povetacicept: Phase 2/3 readout est. (NCT07204275)
DESCRIPTION:Povetacicept\, phase 2/3\, Primary Membranous Nephropathy.\nStu
 dy: Evaluation of Efficacy\, Safety\, and Tolerability of Povetacicept in 
 Participants With Primary Membranous Nephropathy (pMN)\nEstimated primary 
 completion: 27 June 2029. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/povetacicept#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07204275
URL:https://assetmemo.bio/drug/povetacicept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07807995-10841@assetmemo.bio
DTSTAMP:20261121T004948Z
DTSTART;VALUE=DATE:20291228
DTEND;VALUE=DATE:20291229
SUMMARY:Povetacicept: Phase 3 readout est. (NCT07807995)
DESCRIPTION:Povetacicept\, phase 3\, IgA Nephropathy.\nStudy: A Phase 3 Ope
 n-Label Study of Long-term Treatment With Povetacicept in Adults With Immu
 noglobulin A Nephropathy\nEstimated primary completion: 28 December 2029. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/povetacicept#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07807995
URL:https://assetmemo.bio/drug/povetacicept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
